HEADER IMMUNE SYSTEM/VIRAL PROTEIN 29-APR-21 7MLZ TITLE CRYO-EM STRUCTURE OF SARS-COV-2 SPIKE IN COMPLEX WITH NEUTRALIZING TITLE 2 ANTIBODY B1-182.1 THAT TARGETS THE RECEPTOR-BINDING DOMAIN COMPND MOL_ID: 1; COMPND 2 MOLECULE: SPIKE PROTEIN S1; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: RECEPTOR BINDING DOMAIN, UNP RESIDUES 331-527; COMPND 5 ENGINEERED: YES; COMPND 6 MOL_ID: 2; COMPND 7 MOLECULE: B1-182.1 FAB HEAVY CHAIN; COMPND 8 CHAIN: H; COMPND 9 ENGINEERED: YES; COMPND 10 MOL_ID: 3; COMPND 11 MOLECULE: B1-182.1 FAB LIGHT CHAIN; COMPND 12 CHAIN: L; COMPND 13 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS SOURCE 3 2; SOURCE 4 ORGANISM_COMMON: 2019-NCOV, SARS-COV-2; SOURCE 5 ORGANISM_TAXID: 2697049; SOURCE 6 GENE: S, 2; SOURCE 7 EXPRESSION_SYSTEM: HOMO SAPIENS; SOURCE 8 EXPRESSION_SYSTEM_TAXID: 9606; SOURCE 9 EXPRESSION_SYSTEM_CELL_LINE: HEK293F; SOURCE 10 MOL_ID: 2; SOURCE 11 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 12 ORGANISM_TAXID: 9606; SOURCE 13 EXPRESSION_SYSTEM: HOMO SAPIENS; SOURCE 14 EXPRESSION_SYSTEM_TAXID: 9606; SOURCE 15 EXPRESSION_SYSTEM_CELL_LINE: HEK293F; SOURCE 16 MOL_ID: 3; SOURCE 17 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 18 ORGANISM_TAXID: 9606; SOURCE 19 EXPRESSION_SYSTEM: HOMO SAPIENS; SOURCE 20 EXPRESSION_SYSTEM_TAXID: 9606; SOURCE 21 EXPRESSION_SYSTEM_CELL_LINE: HEK293F KEYWDS SARS-COV-2, RECEPTOR-BINDING DOMAIN, ANTIBODY, IMMUNE SYSTEM-VIRAL KEYWDS 2 PROTEIN COMPLEX EXPDTA ELECTRON MICROSCOPY AUTHOR T.ZHOU,T.TSYBOVSKY,P.D.KWONG REVDAT 4 25-AUG-21 7MLZ 1 JRNL REVDAT 3 11-AUG-21 7MLZ 1 REMARK REVDAT 2 04-AUG-21 7MLZ 1 JRNL REVDAT 1 28-JUL-21 7MLZ 0 JRNL AUTH L.WANG,T.ZHOU,Y.ZHANG,E.S.YANG,C.A.SCHRAMM,W.SHI,A.PEGU, JRNL AUTH 2 O.K.OLONINIYI,A.R.HENRY,S.DARKO,S.R.NARPALA,C.HATCHER, JRNL AUTH 3 D.R.MARTINEZ,Y.TSYBOVSKY,E.PHUNG,O.M.ABIONA,A.ANTIA, JRNL AUTH 4 E.M.CALE,L.A.CHANG,M.CHOE,K.S.CORBETT,R.L.DAVIS, JRNL AUTH 5 A.T.DIPIAZZA,I.J.GORDON,S.H.HAIT,T.HERMANUS,P.KGAGUDI, JRNL AUTH 6 F.LABOUNE,K.LEUNG,T.LIU,R.D.MASON,A.F.NAZZARI,L.NOVIK, JRNL AUTH 7 S.O'CONNELL,S.O'DELL,A.S.OLIA,S.D.SCHMIDT,T.STEPHENS, JRNL AUTH 8 C.D.STRINGHAM,C.A.TALANA,I.T.TENG,D.A.WAGNER,A.T.WIDGE, JRNL AUTH 9 B.ZHANG,M.ROEDERER,J.E.LEDGERWOOD,T.J.RUCKWARDT, JRNL AUTH10 M.R.GAUDINSKI,P.L.MOORE,N.A.DORIA-ROSE,R.S.BARIC,B.S.GRAHAM, JRNL AUTH11 A.B.MCDERMOTT,D.C.DOUEK,P.D.KWONG,J.R.MASCOLA,N.J.SULLIVAN, JRNL AUTH12 J.MISASI JRNL TITL ULTRAPOTENT ANTIBODIES AGAINST DIVERSE AND HIGHLY JRNL TITL 2 TRANSMISSIBLE SARS-COV-2 VARIANTS. JRNL REF SCIENCE V. 373 2021 JRNL REFN ESSN 1095-9203 JRNL PMID 34210892 JRNL DOI 10.1126/SCIENCE.ABH1766 REMARK 2 REMARK 2 RESOLUTION. 3.71 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 SOFTWARE PACKAGES : CRYOSPARC, CRYOSPARC, COOT, CRYOSPARC, REMARK 3 PHENIX REMARK 3 RECONSTRUCTION SCHEMA : NULL REMARK 3 REMARK 3 EM MAP-MODEL FITTING AND REFINEMENT REMARK 3 PDB ENTRY : 7KLS REMARK 3 REFINEMENT SPACE : REAL REMARK 3 REFINEMENT PROTOCOL : RIGID BODY FIT REMARK 3 REFINEMENT TARGET : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE : NULL REMARK 3 REMARK 3 FITTING PROCEDURE : NULL REMARK 3 REMARK 3 EM IMAGE RECONSTRUCTION STATISTICS REMARK 3 NOMINAL PIXEL SIZE (ANGSTROMS) : NULL REMARK 3 ACTUAL PIXEL SIZE (ANGSTROMS) : NULL REMARK 3 EFFECTIVE RESOLUTION (ANGSTROMS) : 3.710 REMARK 3 NUMBER OF PARTICLES : 208776 REMARK 3 CTF CORRECTION METHOD : PHASE FLIPPING AND AMPLITUDE REMARK 3 CORRECTION REMARK 3 REMARK 3 EM RECONSTRUCTION MAGNIFICATION CALIBRATION: NULL REMARK 3 REMARK 3 OTHER DETAILS: LOCAL REFINEMENT WITH PARTICLES SUBTRACTED FROM REMARK 3 SARS-COV-2 SPIKE-ANTIBODY COMPLEX. REMARK 4 REMARK 4 7MLZ COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 30-APR-21. REMARK 100 THE DEPOSITION ID IS D_1000256513. REMARK 245 REMARK 245 EXPERIMENTAL DETAILS REMARK 245 RECONSTRUCTION METHOD : SINGLE PARTICLE REMARK 245 SPECIMEN TYPE : NULL REMARK 245 REMARK 245 ELECTRON MICROSCOPE SAMPLE REMARK 245 SAMPLE TYPE : PARTICLE REMARK 245 PARTICLE TYPE : POINT REMARK 245 NAME OF SAMPLE : SARS-COV-2 SPIKE RBD IN COMPLEX REMARK 245 WITH NEUTRALIZING ANTIBODY B1- REMARK 245 182.1 REMARK 245 SAMPLE CONCENTRATION (MG ML-1) : 0.50 REMARK 245 SAMPLE SUPPORT DETAILS : NULL REMARK 245 SAMPLE VITRIFICATION DETAILS : BLOT FOR 4 SECONDS BEFORE REMARK 245 PLUGGING. REMARK 245 SAMPLE BUFFER : NULL REMARK 245 PH : 7.40 REMARK 245 SAMPLE DETAILS : LOCAL REFINEMENT OF DATA REMARK 245 COLLECTED FOR THE COMPLEX MADE BY MIXING THE SARS-COV-2 SPIKE REMARK 245 PROTEIN AND FAB FRAGMENT OF ANTIBODY AT A MOLAR RATIO OF 1:3.6. REMARK 245 USED PARTICLE SUBSTRACTION TO OBTAIN RBD-FAB PORTION FOR REMARK 245 REFINEMENT. REMARK 245 REMARK 245 DATA ACQUISITION REMARK 245 DATE OF EXPERIMENT : NULL REMARK 245 NUMBER OF MICROGRAPHS-IMAGES : NULL REMARK 245 TEMPERATURE (KELVIN) : NULL REMARK 245 MICROSCOPE MODEL : FEI TITAN KRIOS REMARK 245 DETECTOR TYPE : OTHER REMARK 245 MINIMUM DEFOCUS (NM) : 1100.00 REMARK 245 MAXIMUM DEFOCUS (NM) : 2100.00 REMARK 245 MINIMUM TILT ANGLE (DEGREES) : NULL REMARK 245 MAXIMUM TILT ANGLE (DEGREES) : NULL REMARK 245 NOMINAL CS : 2.70 REMARK 245 IMAGING MODE : BRIGHT FIELD REMARK 245 ELECTRON DOSE (ELECTRONS NM**-2) : 4000.00 REMARK 245 ILLUMINATION MODE : FLOOD BEAM REMARK 245 NOMINAL MAGNIFICATION : 105000 REMARK 245 CALIBRATED MAGNIFICATION : NULL REMARK 245 SOURCE : FIELD EMISSION GUN REMARK 245 ACCELERATION VOLTAGE (KV) : 300 REMARK 245 IMAGING DETAILS : NULL REMARK 247 REMARK 247 ELECTRON MICROSCOPY REMARK 247 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM ELECTRON REMARK 247 MICROSCOPY DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE REMARK 247 THAT CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES REMARK 247 ON THESE RECORDS ARE MEANINGLESS EXCEPT FOR THE CALCULATION REMARK 247 OF THE STRUCTURE FACTORS. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, H, L, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ASN A 331 REMARK 465 GLN H 1 REMARK 465 SER H 128 REMARK 465 LYS H 129 REMARK 465 SER H 130 REMARK 465 THR H 131 REMARK 465 SER H 132 REMARK 465 GLY H 133 REMARK 465 GLY H 134 REMARK 465 LYS H 214 REMARK 465 SER H 215 REMARK 465 CYS H 216 REMARK 465 ASP H 217 REMARK 465 LYS H 218 REMARK 465 GLU L 213 REMARK 465 CYS L 214 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 SER H 113 OG REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 OG1 THR H 28 O CYS H 97 2.15 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 CYS A 379 CA - CB - SG ANGL. DEV. = 8.3 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 THR A 333 179.78 61.97 REMARK 500 PRO A 337 61.39 -68.06 REMARK 500 ALA A 348 -121.48 0.65 REMARK 500 SER A 349 -173.72 -170.85 REMARK 500 ALA A 352 35.17 -93.53 REMARK 500 TYR A 380 141.89 -37.65 REMARK 500 PRO A 412 75.13 -67.14 REMARK 500 GLN A 414 -137.47 48.59 REMARK 500 ASN A 440 -169.52 -117.52 REMARK 500 LEU A 441 65.58 62.43 REMARK 500 ASP A 442 44.74 71.38 REMARK 500 TYR A 451 60.88 63.89 REMARK 500 LEU A 461 169.68 66.07 REMARK 500 PHE A 464 -4.52 70.96 REMARK 500 ALA A 475 29.28 -140.04 REMARK 500 ASN A 487 -137.94 55.05 REMARK 500 LYS H 12 -169.13 -129.02 REMARK 500 PRO H 14 74.11 -68.04 REMARK 500 THR H 16 -66.11 -95.88 REMARK 500 SER H 17 174.19 179.46 REMARK 500 ALA H 40 -169.88 -163.89 REMARK 500 ILE H 48 -63.14 -109.48 REMARK 500 TYR H 91 -174.08 57.08 REMARK 500 ASP H 144 61.68 61.66 REMARK 500 ASN H 155 -2.82 64.79 REMARK 500 THR H 160 36.14 -98.35 REMARK 500 SER H 161 37.64 -92.05 REMARK 500 PRO H 167 -177.15 -69.25 REMARK 500 LEU H 178 -168.46 -161.62 REMARK 500 SER H 186 -169.95 -166.81 REMARK 500 SER H 188 40.48 -109.13 REMARK 500 GLN H 192 167.70 59.66 REMARK 500 CYS H 196 38.10 -96.98 REMARK 500 SER L 31 -6.29 69.27 REMARK 500 SER L 52 12.05 -140.93 REMARK 500 SER L 53 -167.45 -162.94 REMARK 500 SER L 63 117.64 -162.05 REMARK 500 THR L 109 70.52 60.07 REMARK 500 SER L 202 -137.40 62.27 REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: EMD-23498 RELATED DB: EMDB REMARK 900 RELATED ID: EMD-23914 RELATED DB: EMDB REMARK 900 SARS-COV-2 SPIKE RBD IN COMPLEX WITH B1-182.1 FAB FRAGMENT DBREF 7MLZ A 331 527 UNP P0DTC2 SPIKE_SARS2 331 527 DBREF 7MLZ H 1 218 PDB 7MLZ 7MLZ 1 218 DBREF 7MLZ L 1 214 PDB 7MLZ 7MLZ 1 214 SEQRES 1 A 197 ASN ILE THR ASN LEU CYS PRO PHE GLY GLU VAL PHE ASN SEQRES 2 A 197 ALA THR ARG PHE ALA SER VAL TYR ALA TRP ASN ARG LYS SEQRES 3 A 197 ARG ILE SER ASN CYS VAL ALA ASP TYR SER VAL LEU TYR SEQRES 4 A 197 ASN SER ALA SER PHE SER THR PHE LYS CYS TYR GLY VAL SEQRES 5 A 197 SER PRO THR LYS LEU ASN ASP LEU CYS PHE THR ASN VAL SEQRES 6 A 197 TYR ALA ASP SER PHE VAL ILE ARG GLY ASP GLU VAL ARG SEQRES 7 A 197 GLN ILE ALA PRO GLY GLN THR GLY LYS ILE ALA ASP TYR SEQRES 8 A 197 ASN TYR LYS LEU PRO ASP ASP PHE THR GLY CYS VAL ILE SEQRES 9 A 197 ALA TRP ASN SER ASN ASN LEU ASP SER LYS VAL GLY GLY SEQRES 10 A 197 ASN TYR ASN TYR LEU TYR ARG LEU PHE ARG LYS SER ASN SEQRES 11 A 197 LEU LYS PRO PHE GLU ARG ASP ILE SER THR GLU ILE TYR SEQRES 12 A 197 GLN ALA GLY SER THR PRO CYS ASN GLY VAL GLU GLY PHE SEQRES 13 A 197 ASN CYS TYR PHE PRO LEU GLN SER TYR GLY PHE GLN PRO SEQRES 14 A 197 THR ASN GLY VAL GLY TYR GLN PRO TYR ARG VAL VAL VAL SEQRES 15 A 197 LEU SER PHE GLU LEU LEU HIS ALA PRO ALA THR VAL CYS SEQRES 16 A 197 GLY PRO SEQRES 1 H 228 GLN MET GLN LEU VAL GLN SER GLY PRO GLU VAL LYS LYS SEQRES 2 H 228 PRO GLY THR SER VAL LYS VAL SER CYS LYS ALA SER GLY SEQRES 3 H 228 PHE THR PHE THR SER SER ALA VAL GLN TRP VAL ARG GLN SEQRES 4 H 228 ALA ARG GLY GLN ARG LEU GLU TRP ILE GLY TRP ILE VAL SEQRES 5 H 228 VAL GLY SER GLY ASN THR ASN TYR ALA GLN LYS PHE GLN SEQRES 6 H 228 GLU ARG VAL THR ILE THR ARG ASP MET SER THR SER THR SEQRES 7 H 228 ALA TYR MET GLU LEU SER SER LEU ARG SER GLU ASP THR SEQRES 8 H 228 ALA VAL TYR TYR CYS ALA ALA PRO TYR CYS SER GLY GLY SEQRES 9 H 228 SER CYS PHE ASP GLY PHE ASP ILE TRP GLY GLN GLY THR SEQRES 10 H 228 MET VAL THR VAL SER SER ALA SER THR LYS GLY PRO SER SEQRES 11 H 228 VAL PHE PRO LEU ALA PRO SER SER LYS SER THR SER GLY SEQRES 12 H 228 GLY THR ALA ALA LEU GLY CYS LEU VAL LYS ASP TYR PHE SEQRES 13 H 228 PRO GLU PRO VAL THR VAL SER TRP ASN SER GLY ALA LEU SEQRES 14 H 228 THR SER GLY VAL HIS THR PHE PRO ALA VAL LEU GLN SER SEQRES 15 H 228 SER GLY LEU TYR SER LEU SER SER VAL VAL THR VAL PRO SEQRES 16 H 228 SER SER SER LEU GLY THR GLN THR TYR ILE CYS ASN VAL SEQRES 17 H 228 ASN HIS LYS PRO SER ASN THR LYS VAL ASP LYS LYS VAL SEQRES 18 H 228 GLU PRO LYS SER CYS ASP LYS SEQRES 1 L 215 GLU ILE VAL LEU THR GLN SER PRO GLY THR LEU SER LEU SEQRES 2 L 215 SER PRO GLY GLU ARG ALA THR LEU SER CYS ARG ALA SER SEQRES 3 L 215 GLN SER VAL SER SER SER TYR LEU ALA TRP TYR GLN GLN SEQRES 4 L 215 LYS PRO GLY GLN ALA PRO ARG LEU LEU ILE TYR GLY ALA SEQRES 5 L 215 SER SER ARG ALA THR GLY PHE PRO ASP ARG PHE SER GLY SEQRES 6 L 215 SER GLY SER GLY THR ASP PHE THR LEU THR ILE SER ARG SEQRES 7 L 215 LEU GLU PRO GLU ASP PHE ALA VAL TYR TYR CYS GLN GLN SEQRES 8 L 215 TYR GLY ASN SER PRO TRP THR PHE GLY GLN GLY THR LYS SEQRES 9 L 215 VAL GLU ILE ARG ARG THR VAL ALA ALA PRO SER VAL PHE SEQRES 10 L 215 ILE PHE PRO PRO SER ASP GLU GLN LEU LYS SER GLY THR SEQRES 11 L 215 ALA SER VAL VAL CYS LEU LEU ASN ASN PHE TYR PRO ARG SEQRES 12 L 215 GLU ALA LYS VAL GLN TRP LYS VAL ASP ASN ALA LEU GLN SEQRES 13 L 215 SER GLY ASN SER GLN GLU SER VAL THR GLU GLN ASP SER SEQRES 14 L 215 LYS ASP SER THR TYR SER LEU SER SER THR LEU THR LEU SEQRES 15 L 215 SER LYS ALA ASP TYR GLU LYS HIS LYS VAL TYR ALA CYS SEQRES 16 L 215 GLU VAL THR HIS GLN GLY LEU SER SER PRO VAL THR LYS SEQRES 17 L 215 SER PHE ASN ARG GLY GLU CYS HET NAG B 1 14 HET NAG B 2 14 HET BMA B 3 11 HET MAN B 4 11 HET MAN B 5 11 HETNAM NAG 2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSE HETNAM BMA BETA-D-MANNOPYRANOSE HETNAM MAN ALPHA-D-MANNOPYRANOSE HETSYN NAG N-ACETYL-BETA-D-GLUCOSAMINE; 2-ACETAMIDO-2-DEOXY-BETA- HETSYN 2 NAG D-GLUCOSE; 2-ACETAMIDO-2-DEOXY-D-GLUCOSE; 2-ACETAMIDO- HETSYN 3 NAG 2-DEOXY-GLUCOSE; N-ACETYL-D-GLUCOSAMINE HETSYN BMA BETA-D-MANNOSE; D-MANNOSE; MANNOSE HETSYN MAN ALPHA-D-MANNOSE; D-MANNOSE; MANNOSE FORMUL 4 NAG 2(C8 H15 N O6) FORMUL 4 BMA C6 H12 O6 FORMUL 4 MAN 2(C6 H12 O6) HELIX 1 AA1 PRO A 337 ASN A 343 1 7 HELIX 2 AA2 TYR A 365 ASN A 370 1 6 HELIX 3 AA3 GLY A 404 ILE A 410 5 7 HELIX 4 AA4 MET H 73 THR H 77 5 5 HELIX 5 AA5 SER L 121 LYS L 126 5 6 SHEET 1 AA1 4 LYS A 356 ILE A 358 0 SHEET 2 AA1 4 VAL A 395 ALA A 397 -1 O VAL A 395 N ILE A 358 SHEET 3 AA1 4 TYR A 508 SER A 514 -1 O SER A 514 N TYR A 396 SHEET 4 AA1 4 PHE A 400 ILE A 402 -1 N PHE A 400 O VAL A 510 SHEET 1 AA2 4 LYS A 356 ILE A 358 0 SHEET 2 AA2 4 VAL A 395 ALA A 397 -1 O VAL A 395 N ILE A 358 SHEET 3 AA2 4 TYR A 508 SER A 514 -1 O SER A 514 N TYR A 396 SHEET 4 AA2 4 GLY A 431 ASN A 437 -1 N ILE A 434 O VAL A 511 SHEET 1 AA3 2 LEU H 4 GLN H 6 0 SHEET 2 AA3 2 CYS H 22 ALA H 24 -1 O LYS H 23 N VAL H 5 SHEET 1 AA4 2 VAL H 11 LYS H 12 0 SHEET 2 AA4 2 THR H 110 VAL H 111 1 O THR H 110 N LYS H 12 SHEET 1 AA5 3 VAL H 18 LYS H 19 0 SHEET 2 AA5 3 TYR H 79 LEU H 82 -1 O LEU H 82 N VAL H 18 SHEET 3 AA5 3 VAL H 67 THR H 70 -1 N THR H 70 O TYR H 79 SHEET 1 AA6 3 ALA H 33 ARG H 38 0 SHEET 2 AA6 3 GLU H 46 VAL H 52 -1 O ILE H 51 N VAL H 34 SHEET 3 AA6 3 ASN H 56 THR H 57 -1 O ASN H 56 N VAL H 52 SHEET 1 AA7 2 ALA H 93 ALA H 94 0 SHEET 2 AA7 2 ILE H 102 TRP H 103 -1 O ILE H 102 N ALA H 94 SHEET 1 AA8 4 SER H 120 LEU H 124 0 SHEET 2 AA8 4 ALA H 137 TYR H 145 -1 O LYS H 143 N SER H 120 SHEET 3 AA8 4 TYR H 176 THR H 183 -1 O VAL H 182 N LEU H 138 SHEET 4 AA8 4 HIS H 164 LEU H 170 -1 N HIS H 164 O VAL H 181 SHEET 1 AA9 2 VAL H 198 HIS H 200 0 SHEET 2 AA9 2 THR H 205 VAL H 207 -1 O VAL H 207 N VAL H 198 SHEET 1 AB1 2 THR L 10 SER L 12 0 SHEET 2 AB1 2 LYS L 103 GLU L 105 1 O GLU L 105 N LEU L 11 SHEET 1 AB2 2 THR L 20 ARG L 24 0 SHEET 2 AB2 2 ASP L 70 THR L 74 -1 O LEU L 73 N LEU L 21 SHEET 1 AB3 2 LEU L 33 GLN L 37 0 SHEET 2 AB3 2 TYR L 86 GLN L 90 -1 O TYR L 87 N TYR L 36 SHEET 1 AB4 4 ILE L 117 PHE L 118 0 SHEET 2 AB4 4 VAL L 132 LEU L 135 -1 O VAL L 133 N PHE L 118 SHEET 3 AB4 4 LEU L 175 LEU L 179 -1 O SER L 177 N CYS L 134 SHEET 4 AB4 4 GLN L 160 VAL L 163 -1 N SER L 162 O SER L 176 SHEET 1 AB5 2 VAL L 146 GLN L 147 0 SHEET 2 AB5 2 GLU L 195 VAL L 196 -1 O GLU L 195 N GLN L 147 SSBOND 1 CYS A 336 CYS A 361 1555 1555 2.03 SSBOND 2 CYS A 379 CYS A 432 1555 1555 2.05 SSBOND 3 CYS A 391 CYS A 525 1555 1555 2.03 SSBOND 4 CYS A 480 CYS A 488 1555 1555 2.03 SSBOND 5 CYS H 22 CYS H 92 1555 1555 2.04 SSBOND 6 CYS H 97 CYS H 100B 1555 1555 2.04 SSBOND 7 CYS H 140 CYS H 196 1555 1555 2.03 SSBOND 8 CYS L 23 CYS L 88 1555 1555 2.04 SSBOND 9 CYS L 134 CYS L 194 1555 1555 2.03 LINK ND2 ASN A 343 C1 NAG B 1 1555 1555 1.45 LINK O4 NAG B 1 C1 NAG B 2 1555 1555 1.45 LINK O4 NAG B 2 C1 BMA B 3 1555 1555 1.44 LINK O3 BMA B 3 C1 MAN B 4 1555 1555 1.45 LINK O6 BMA B 3 C1 MAN B 5 1555 1555 1.44 CISPEP 1 SER L 94 PRO L 95 0 -0.86 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000